GHENT, Belgium, 6 March 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA , has presented new data from a Phase Ib study demonstrating strong efficacy with the bi-specific anti-IL-17A/F Nanobody® in patients with moderate-to-severe chronic plaque psoriasis. The results were presented at the 75th Annual Meeting of the American Academy of Dermatology Conference, taking place from 3-7 March 2017, in Orlando, Florida.